Shorter Antibiotic Course Safe, Effective for Uncomplicated Childhood CAP
The randomized, double-blind, placebo-controlled study included a total of 380 patients aged 6 to 71 months with nonsevere CAP.
Pediatrics
FDA Extends Review Period for Gene Therapies for Beta-Thalassemia, Cerebral Adrenoleukodystrophy
The FDA extended the target dates for beti-cel and eli-cel to allow time to review additional clinical information for both applications.
Influenza Vaccination Cuts Risk of Critical Illness in Children
During a season predominated by 2 vaccine-mismatched viruses, vaccination was estimated to reduce the risk of life-threatening influenza illness by 75%.
Pediatric Antibiotic Prescribing Dropped During Pandemic
Decrease in antibiotic prescriptions in pediatric primary care driven by reduced volume of visits for respiratory tract infections
Nearly 600,000 US Children Had COVID-19 Last Week
Since the start of the pandemic, nearly 8.5 million U.S. children have tested positive for COVID-19
CDC Recommends COVID-19 Vaccine Booster Dose for 12- to 15-Year-Olds
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommends the use of a single booster dose of the Pfizer-BioNTech COVID-19 vaccine in individuals 12 to 15 years of age at least 5 months after completion of the primary series. The advisory panel’s recommendations follow a similar decision made by…
Dolutegravir-Based ART Superior for Children, Teens With HIV
Rate of serious adverse events similar for participants receiving dolutegravir, standard care as first-, second-line treatment for HIV-1 infection
Maternal Hormonal Contraception, CNS Tumors Not Linked in Children
No significant association seen for recent or previous maternal hormonal contraception use with CNS tumors in children younger than 20 years
Rexulti Approval Expanded to Include Adolescents With Schizophrenia
The approval was based on data from an ongoing phase 3 trial evaluating the safety and tolerability of brexpiprazole as maintenance treatment of 194 patients aged 13 to 17 years with schizophrenia.
Cosentyx Approved for Enthesitis-Related Arthritis, Juvenile Psoriatic Arthritis
The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA.
